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ABSTRACT
Clinicians are expected to select a therapy
based on their appraisal of evidence on bene-
fit-to-risk profiles of therapies. In the manage-
ment of relapsing-remitting multiple sclerosis
(RRMS), evidence is typically expressed in
terms of risk (proportion) of event, risk reduc-
tion, relative and hazard rate reduction, or
relative reduction in the mean number of
magnetic resonance imaging lesions. Inter-
preting treatment effect using these measures
from a RRMS clinical trial is fairly reliable;
however, this might not be the case when
treatment effect is expressed in terms of the
number needed to treat (NNT). The objective
of this review is to discuss the utility of NNT in
RRMS trials. This article presents an overview
of the methodological definition and charac-
teristics of NNT as well as the relative merit of
NNT use in RRMS controlled clinical trials,
where endpoints are typically time-to-event
and frequency of recurrent events. The authors
caution against using NNT in multiple sclero-
sis, a clinically heterogeneous disease that can
change course and severity unpredictably. The
authors also caution against the use of NNT to
interpret results in comparative trials where
the absolute risk difference is not statistically
significant, computing NNT using the time--
to-event endpoint at intermediate time points,
computing NNT using the annualized relapse
rate, and comparing NNT across trials.
Keywords: Absolute risk difference; Annualized
relapse rate; Controlled clinical trials; Number
needed to treat; Relapsing-remitting multiple
sclerosis; Statistical inference
INTRODUCTION
The number needed to treat (NNT) was origi-
nally used to provide greater clinical relevance
to a small risk difference (RD) [1–3], particularly
when that RD was converted to a percentage of
control. For example, when the control (C) rate
is 1% and the treatment (T) rate is 0.67% for an
event of medical interest (e.g., myocardial
infarction [MI]), the estimated absolute risk
difference (ARD) is 0.0067–0.01 = 0.0033 or
0.33%. This becomes 33% (0.0033/0.01) when
expressed as a percentage of C.
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An interpretation of the ARD using the
example above is that, on average, among
1000 patients treated with T and 1000 treated
with C, one could expect 3.3 fewer patients to
have the event in the T group than in the C
group. Alternatively, one may wish to deter-
mine how many patients need to be treated to
have one fewer event in the T group com-
pared with the C group. The answer is pro-
vided by the NNT, which in this case would
be 1/0.0033 = 303.03 patients. In general,
NNT = 1/ARD. NNT is usually rounded up to
the nearest larger integer, which in this
example is 304.
There is much debate in the literature [4, 5]
about whether NNT is a useful measure to
summarize treatment effect from a clinical trial
with binary efficacy endpoints. The proponents
of the summary measure find it appealing
because they believe it is easy to interpret.
However, some argue [6–8] that the basic defi-
nition of NNT is flawed and that NNT lacks
statistical content.
Initially, it was coronary heart disease risk
trials that spawned the use of NNT. These trials
were large due to the relatively rare occurrence
of the event in question and because of the large
power needed to detect a clinically meaningful
RD between the T and C groups. More recently,
NNT has been used to interpret outcome data
from clinical trials in many other disease areas,
including multiple sclerosis (MS) [9–13], prob-
ably because of the purported ease of interpre-
tation [14].
There is a need to clarify both the definition
and use of NNT in summarizing outcome data
from comparative relapsing-remitting MS
(RRMS) trials so that reported NNTs can be
critically appraised. This article provides an
overview of the definition and methodological
characteristics of NNT, and discusses the rela-
tive merits of its use in MS clinical trials, where
endpoints are typically time-to-event or fre-
quency of recurrent events.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
NNT FOR DICHOTOMOUS DATA
Historically, the use of NNT was based on
dichotomous efficacy data and reported in trials
in which T was better than C. In a clinical trial
of MI (see example in the ‘‘Introduction’’), an
NNT of 304 is interpreted as indicating that 304
patients would need to be treated, on average,
with the drug to prevent one MI. Adverse event
(AE) data are collected in such trials and, by
definition, reflect potential harm to the patient,
particularly when the AEs are serious. Therefore,
it is of clinical interest to compute the number
needed to harm (NNH), which implies that the
incidence in the T group is greater than that in
the C group (if the event represents a potential
harm). Of note, if the event represents a benefit,
but its incidence is less in the T group than in
the C group, it would be appropriate to use
NNH instead of NNT. This is another complex-
ity of interpreting NNT.
NNH is computed in the same way as NNT
but represents a different measure. Consider the
trial in the previous example, in which the NNT
for MI was 304 patients. If the rates of protein-
uria were 0.5% in the T group and 0.4% in the C
group, then ARD = 0.001 and NNH = 1000.
Thus, if MI and proteinuria were assessed in the
same trial, 304 patients would need to be trea-
ted, on average, to prevent one fewer patient
experiencing an MI, and 1000 patients would
need to be treated to observe one more patient
with proteinuria.
Statistical Properties of ARD and NNT
Population parameters (e.g., true ARD and NNT)
are infrequently known. Data for a random
sample from the population are used to esti-
mate the parameters. This gives rise to point
estimates. Different samples may contain data
on different individuals. Thus, it is expected
that estimates will vary from one sample to
another.
Point estimates and their variability are used
to compute a confidence interval (CI) with
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lower and upper limits (L, U) on the population
parameter. For any given data, the endpoints L
and U are real numbers. To say that (L, U) is a
95% CI on the true ARD does not mean that the
true ARD will fall within this interval, but rather
that 95% of the intervals derived would contain
the true mean ARD if the experiment was
repeated multiple times.
The statistical methodology for computing
CIs on the true ARD is well established. How-
ever, this is not the case for computing CIs on
the true NNT. There are several reasons for this:
(a) NNT is not defined in the interval (–1, ?1),
(b) the variance of NNT is difficult to estimate
accurately, and (c) the sampling distribution
appears to be triangular [15].
ARD is a summary statistic that synthesizes
event information on patients in the T and C
groups. Therefore, its variance consists of both
within- and between-group variability, and it
can be written in a closed form. This variance is
a primary driver of the length of the CI on ARD.
On the other hand, the NNT is a transformation
of ARD, producing a single point estimate
without quantifiable variability. A point esti-
mate without its associated variability provides
no information for one to judge the proximity
of the sample estimate of treatment effect to the
unknown population parameter (the true
treatment effect) about which one wishes to
make a statistical inference. Therefore, without
an established method for quantifying the
variability of a point estimate, it is impossible to
know whether the estimated treatment effect is
indicative of a real effect (see Hotelling [16]).
Several authors (e.g., Cook and Sackett [2],
Schulzer and Mancini [17], Altman [18], and
Bender [19]) have proposed different methods
for computing the CI on NNT. For instance,
Cook and Sackett [2] proposed computing the
CI on ARD and then inverting and reversing the
order of the endpoint of the interval to get an
approximate CI on NNT.
There are instances, however, where the
method of Cook and Sackett [2] and Altman
[18] for computing CIs on NNT can produce
unreasonable results in which the CI does not
contain the point estimate of NNT. One such
situation is when the ARD is not statistically
significant, in which case the T group may be
descriptively favored over the C group, or vice
versa. When there is no statistically significant
difference between treatment groups, there is
no finite single value corresponding to instan-
ces where NNT is meaningful [8]. For example,
when the estimate of ARD in a clinical trial
comparing T to C was 0.05 and the 95% CI on
the true ARD was (–0.10, ?0.20), the point
estimate of NNT is 20 patients, and by inversion
the approximate 95% CI on NNT has a lower
endpoint of ?5 and an upper endpoint of –10.
Not only is the point estimate of NNT not in the
CI, but the CI is not valid (i.e., a positive lower
limit and negative upper limit).
When there is no meaningful difference
between treatment groups, NNT should not be
computed. This is because when the ARD is not
statistically significant, it is doubtful that the
NNT has a meaningful clinical utility as there is
little or no evidence that the observed ARD
reflects the true state of nature. In general, if the
(L, U) of a CI on the true ARD are negative and
positive, respectively (ARD is not statistically
significant), it is not advisable to generate a CI
on the NNT by inverting the limits and revers-
ing their order.
NNT IN MS CLINICAL TRIALS
Common efficacy outcome data from RRMS
trials include the percentages of patients with
events (estimated as cumulative time-to-event
percentages for disability progression or first
relapse), the frequency of recurrent events (an-
nualized relapse rate [ARR]), and the number of
magnetic resonance imaging lesions. Therapies
showing higher efficacy could also have serious
harmful side effects. Thus, if there is a desire to
compute the NNT for MS therapies, it would be
appropriate to report both the NNT and NNH to
aid the evaluation of the benefit-to-risk profiles
of the treatments. The following discussion is
intended to help with the appraisal of NNT
when computed in MS trials.
Time-to-Event Efficacy Endpoints for NNT
A time-to-event endpoint measures ‘‘if’’ an
event occurred and ‘‘when’’ the event occurred.
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Thus, for time to relapse or disability worsening,
one can obtain the median (or other percentile)
time to relapse or disability worsening as well as
the proportion of patients with these events.
When there is no censoring, the estimated
cumulative percentage of patients with the
event is the same as the binomial proportion
(number relapsed/number at risk). For a time-
to-event endpoint, the definition of NNT may
be applied to cumulative time-to-event per-
centages. If a protocol specifies a fixed period of
treatment, e.g., 2 years, and there is an interest
in estimating the cumulative percentage of
patients with events at 2 years, then time-to-
event methods would have to be used given
that the event is censored in some patients. If
the 2-year cumulative relapse proportions are,
for example, 30% for the T group and 40% for
the C group, then ARD = 0.10 and NNT = 10;
this is interpreted as indicating that 10 patients
would need to be treated for up to 2 years in
order to have, on average, one fewer patient
experiencing a relapse.
NNT could be time dependent; hence, it
should not be computed using time-to-event
methods at intermediate points during the
specified treatment period, as it may not lead to
consistent meaningful results. This is because
NNT would be difficult to interpret for MS trials
where the ARD was smaller early and larger later
in the treatment period, as the implication is
that a greater number of patients would need to
be treated for a shorter period of time and fewer
would need to be treated for a longer period of
time. In the DEFINE study [20], the Kaplan–-
Meier estimates of the proportion of patients
that relapsed at week 24 are 0.167 and 0.110 for
placebo and delayed-release dimethyl fumarate
(DMF; also known as gastro-resistant DMF)
twice daily (BID), respectively. This gives an
NNT of 18, suggesting that 18 patients would
need to be treated for up to 24 weeks in order to
have, on average, one fewer patient experienc-
ing a relapse. However, the Kaplan–Meier esti-
mates of the proportion of patients that
relapsed at week 96 in the same study are 0.461
and 0.270 for placebo and DMF BID, respec-
tively. This gives a NNT of 6; i.e., the same
therapy (DMF) at the same dose and with the
same effect on biology yields a different NNT
than that obtained in the same study when
computed at a different time point. Addition-
ally, NNT does not provide information on the
average or median time before the event occurs.
Therefore, the time (‘‘when’’) aspect of the
time-to-event endpoint is often not reflected by
NNT. Furthermore, NNT could vary between
the first time-to-event and the end of treatment.
Besides, the course and severity of MS can
change unpredictably [21]. Thus, the computa-
tion of NNT at intermediate time points during
a treatment period is of doubtful utility.
ARR for NNT
For recurrent events such as MS relapse, mea-
sures similar to NNT (referred to as NNT-like
measures, NNT-L) have been proposed based on
reducing the occurrence of events [22]. ARR is
computed as the total number of relapses in a
given period divided by the total number of
person-years in that period. Because a patient
may experience more than one relapse over the
period of a study, relapses within each patient
may be correlated. Additionally, the use of
person-years assumes that the probability of
relapse is constant over time. For example, 50
relapses in 100 patients over 10 years of expo-
sure would give the same relapse rate as 50
relapses in 1000 patients for 1 year of exposure.
The idea is that person-years of exposure is the
sum of person-years exposed for each patient
summed over patients. However, because the
change in ARR over time has been documented
in MS, computing NNT using ARR may con-
found well-known changes in ARR over time
[23–25]. We point out that some authors com-
pute NNT-L measures using the definition of
NNT and interpret them as one interprets NNT.
We argue that such an interpretation is wrong.
The event-based NNT-L measure may be
heavily influenced by small numbers of patients
with multiple events (e.g., highly active
patients) and may give a fractional value that is
\1. When such a fractional value is rounded up
to 1, it will suggest that one patient needs to be
treated to prevent one relapse [26].
Table 1 presents hypothetical relapse data
from 20 patients treated over 2 years, showing
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that when some patients have multiple relapses,
the event-based NNT does not equal the tradi-
tional NNT. Thus, it is easy to misinterpret the
event-based NNT in Table 1 as indicating that
five patients need to be treated, on average, to
prevent one relapse. However, this is half the
number of patients that need to be treated to
prevent one relapse when NNT interpretation is
based on the traditional definition of NNT.
Hence, a distinction should be made between
NNT and NNT-L measures. Of note, NNT is
based on ARD: (T%–C%)/100, i.e., the difference
in the percentages of patients with a critical
event of interest by a specified time of exposure.
Therefore, ARR should not be used to compute
NNT.
The original definition of NNT provides an
answer in terms of number of patients. NNT-L
(such as rate per year) does not have this prop-
erty. At best, the computation of such event-
based measures results in the number of
patient-years of treatment, not the number of
patients. For a chronic disease such as MS, in
which treatment may be lifelong, describing
efficacy in terms of a lower number of
patient-years of treatment may not be relevant
for clinical decisions. Again, the fact that MS
disease course and severity can change unpre-
dictably invalidates any attempt to interpret
treatment effect in terms of number of
patient-years of treatment.
Table 2 shows data from two clinical trials
(Copolymer 1 [NCT00004814] and CONFIRM
[NCT00451451]) [27] where glatiramer acetate
(GA) was administered at a dose of 20 mg/day
for 2 years. The first study [28] is a pivotal phase









relapses over 2 years (n)
1 3 1 2
2 2 2 1
3 2 3 1
4 1 4 0
5 0 5 0
6 0 6 0
7 0 7 0
8 0 8 0
9 0 9 0




Total relapses (n) 8 4
ARR 8/20 PY = 0.40 4/20 PY = 0.20
Traditional NNT 1/(0.40–0.30) = 10
Event-based NNT 1/(0.40–0.20) = 5
ARR annualized relapse rate, NNT number needed to treat, PY patient-years
Neurol Ther
III comparative trial of patients with RRMS, and
the second is a pivotal comparative trial of oral
DMF, in which GA was included as a reference
comparator for assay sensitivity [27]. The same
relative rate reduction (RRR) vs. placebo on ARR
was seen for Copolymer 1 and CONFIRM: 30%
and 29%, respectively (Table 2). This is despite
obtaining different NNTs from ARR and ARD.
The fallacy in the event-based NNT from the
two studies suggests that four and ten patients,
respectively, would need to be treated with GA
for one patient to benefit from treatment.
However, when the traditional definition of
NNT is applied to ARD, the NNT is 15 and 12,
respectively.
Two clinical trials (DEFINE [NCT00420212]
and CONFIRM [20, 27]) assessed DMF 240 mg
BID over a period of 2 years. Table 3 details
different RRRs on ARR for the two studies,
identical NNTs computed from ARR and differ-
ent NNTs computed from ARD. The RRR vs.
placebo was 53% and 44%, respectively, for
DEFINE and CONFIRM. However, the NNTs
computed from ARR were the same for both
studies (6), and the NNTs computed from ARD
were different from the NNTs computed from
ARR. Because the NNTs computed using ARR
from the DEFINE and CONFIRM studies are
identical, the known changes in ARR over time
are obscured [23–25].
Direct Comparison of NNT Across Trials
Comparison of NNTs across MS trials warrants
caution because of the possible difference in the
underlying baseline risk between studies. Even
though the baseline risk may be the same in the
overall study populations, the baseline risk may
differ within the levels of disease severity.
Specifically, in MS trials, the computed NNT
values in two studies may be the same and may
suggest a treatment benefit in the overall study
population, whereas the benefit might be lim-
ited to patient groups with low or intermediate
risk, or who are newly diagnosed or treatment
naı¨ve. Thus, patient groups with a treatment
benefit may differ across studies. Because the
design, baseline characteristics, and percentages
of these risk groups are likely to differ across
studies, it should not be surprising that the NNT
is different when compared across trials for the
same therapy. As reported in Table 2, not only
were the estimated NNTs for the comparison of
GA vs. placebo different in the Copolymer 1 and
Table 2 Example of the same RRR but different NNT values from ARR and ARD
Results for GA Copolymer 1 CONFIRM
Placebo group ARR 0.84 (n = 126) 0.40 (n = 363)
Treatment group ARR 0.59 (n = 125) 0.29 (n = 350)
Absolute ARR difference 0.25 0.11
Event-based NNT 4 10
RRR vs. placebo (%) 30a,b 29a,b
Proportion of placebo group who were relapse-free 0.27 0.59
Proportion of treatment group who were relapse-free 0.34 0.68
ARD 0.07 0.09
Traditional NNT 15 12
Data from the Copolymer 1 and CONFIRM MS clinical trials [25, 26]
ARD absolute risk difference, ARR annualized relapse rate, GA glatiramer acetate, MS multiple sclerosis, NNT number




CONFIRM trials, but the event-based and tra-
ditional NNTs produced conflicting results. The
event-based NNT from Copolymer 1 was lower
than that in the CONFIRM study; however, the
converse was true with the traditional NNT.
Additionally, ARDs, and hence NNTs, are
greatly influenced by placebo risks and rates;
therefore, they are study specific and cannot be
generalized to all MS populations or compared
across studies. As indicated by the GA example
above, when comparing across studies, it is
possible to arrive at a different conclusion using
different or the same endpoints. It is only
appropriate to compare NNTs directly when
outcomes, study durations, and reference pop-
ulations are similar, as results are directly rela-
ted to the control or comparison group.
Furthermore, it is not advisable to perform a
meta-analysis of individual NNT estimates from
a series of clinical trials directly comparing
treatments to get an overall NNT across the
collection of trials. There are many reasons for
this: (a) incompatibility between the average
NNT from the meta-analysis as contrasted with
the NNT produced by reciprocating the inverse
of the average ARD from a meta-analysis; (b) the
variance of individual NNTs is approximate, so
the variance of the overall estimate of NNT
across trials would compound the approxima-
tion; and (c) the variability of the control rate
across trials may be large even when the ARD
and NNT are consistent across trials, which
impacts the interpretation of the combined
estimate of NNT across trials (e.g., 100% T vs.
99% C and 5% T vs. 4% C both lead to an NNT
of 100). Smeeth et al. [29] questioned the via-
bility of conducting meta-analyses based on
NNT. They acknowledge that, although the
results are sometimes informative, they are
usually misleading. In conclusion, if clinical
trials are sufficiently similar to substantiate a
scientifically meaningful meta-analysis of the
RD or ARD, then meta-analysis [30] of RD or
ARD across the trials should be performed to get
an overall RD or ARD, after which the definition
of NNT can be applied to the overall ARD.
CONCLUSION
This article provides a review of the definition
and methodological characteristics of NNT; it
also discusses the relative merits of its use in
Table 3 Example of different RRRs but the same NNT calculated from ARR. Data from the DEFINE and CONFIRM
MS clinical trials [18, 25]
DMFa 240 mg twice daily
DEFINE CONFIRM
Placebo group ARR 0.36 0.40
Treatment group ARR 0.17 0.22
Absolute ARR difference 0.19 0.18
Event-based NNT 6 6
RRR vs. placebo (%) 53 44
p value vs. placebo \0.0001 \0.001
Proportion of placebo group who were relapse-free 0.54 0.59
Proportion of treatment group who were relapse-free 0.73 0.71
ARD 0.19 0.12
Traditional NNT 6 9
ARD absolute risk difference, ARR annualized relapse rate, MS multiple sclerosis, NNT number needed to treat, RRR
relative rate reduction
a Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF)
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comparative clinical RRMS trials. The authors
caution against: (a) the use of NNT in compar-
ative trials where the ARD is not statistically
significant, (b) computing NNT using a time--
to-event endpoint at intermediate time points,
(c) computing NNT using ARR, and (d) making
comparisons or performing inferential analyses
of NNT across trials.
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